Bristol-Myers Squibb Company | TalkMarkets

Latest Posts

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion

Article By: ChinaBio® Today

Saturday, April 6, 2024 1:20 PM EDT

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates for solid tumors.

In this article: INCY, GMAB, CHSYF, BMY, HCM, ZLAB, IVBXF Also: ASND

Read

3 Blue Chip Dividend Stocks To Play Defense

Article By: Dividend Power

Friday, February 2, 2024 9:15 PM EDT

We will discuss 3 long-term blue chip stocks to play defense. They have raised their dividends each year for over ten years, have current yields above the S&P 500 Index average, and should continue to increase their dividends for years to come

In this article: BMY, EMR, QCOM

Read

BMY Stock Dividend Delight: A Blue-Chip’s Healthy Yield

Article By: Tactical Investor

Wednesday, January 31, 2024 7:20 PM EDT

In the grand theater of the financial markets, Bristol-Myers Squibb stands out as a robust performer. Despite the recent pullback, the market sentiment towards this biopharmaceutical titan remains buoyant

In this article: BMY

Read

Bullish Continuation In '24? 3 Market Areas To Watch

Article By: Zacks Investment Research

Wednesday, January 10, 2024 11:00 PM EDT

This article discusses 3 market areas that should outperform dramatically over the next 12 months...

In this article: BMY, NVO, NVS, CYTK, IBB, MSFT, NVDA, IWM, META, GOOGL, KRTX

Read

After A Bruising 2023, Bristol-Myers Squibb Forges A Risky M&A Strategy

Article By: Invezz

Wednesday, December 27, 2023 4:33 AM EDT

Bristol-Myers Squibb was one of the worst performers in the S&P 500 in 2023. BMY has now focused on growth through acquisitions, a high-risk strategy.

In this article: BMY

Read

All Posts